CRESCENT BIOPHARMA INC (CBIO:NASDAQ)
$17.34 0.58 (3.4606%)
Analysed CRESCENT BIOPHARMA INC (CBIO:NASDAQ) News Sources
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
05-01-2026
yahoo.com
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
05-02-2026
yahoo.com
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
18-02-2026
yahoo.com
Crescent Biopharma to Present at March Investor Conferences
23-02-2026
yahoo.com
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
26-02-2026
yahoo.com
Crescent Biopharma: Q4 Earnings Snapshot
26-02-2026
yahoo.com
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
29-04-2026
yahoo.com
Crescent Biopharma to Present at May Investor Conferences
06-05-2026
yahoo.com
Crescent Biopharma to Present at June Investor Conferences
02-06-2026
yahoo.com
Crescent Biopharma Announces Grants of Inducement Awards
26-06-2026
yahoo.com
What is the current price of CRESCENT BIOPHARMA INC (CBIO:NASDAQ)?
The current price of CRESCENT BIOPHARMA INC (CBIO:NASDAQ) is $17.34.
CRESCENT BIOPHARMA INC (CBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of CRESCENT BIOPHARMA INC (CBIO:NASDAQ) since the previous trading day is $0.58.
CRESCENT BIOPHARMA INC (CBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of CRESCENT BIOPHARMA INC (CBIO:NASDAQ) since the previous trading day is 3.4606%.
What is the most recent average sentiment score for CRESCENT BIOPHARMA INC (CBIO:NASDAQ)?
The most recent average sentiment score for CRESCENT BIOPHARMA INC (CBIO:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for CRESCENT BIOPHARMA INC (CBIO:NASDAQ)?
The most recent sentiment for CRESCENT BIOPHARMA INC (CBIO:NASDAQ) is .
SEC-8K** Filing Available For CRESCENT BIOPHARMA INC (CBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.